Skip the main content if you do not want to read it as the next section.
Skip the location trail if you do not want to read it as the next section.
Location trail
HEALTH PROFESSIONALS > TREATMENT GUIDELINES > SPECIFIC CANCERS > LEUKAEMIAUK Treatment Guidelines - Leukaemia
- Guidelines on the diagnosis and management of chronic lymphocytic leukaemia - BCSH - 2004
- Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes - 2003
- Guidance on the use of imatinib for chronic myeloid leukaemia, 2003
- Guideline on the use of Colony Stimulating Factors in Haematological Malignancies - BCSH - 2003
- Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia, NICE - 2001
- Guidelines on the diagnosis and therapy of Hairy cell Leukaemia - British Society for Haemotology - 2000
- Alpha interferon in the treatment of chronic myeloid leukaemia - Wessex Institute - 1996
- Pentostatin and cladribine for hairy cell leukaemia - Wessex Institute - 1995
- Guidelines on the provision of facilities for the care of adult patients with haematological malignancies. (including leukaemia, lymphoma and severe bone marrow failure.) – BCSH - 1995
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia - BCSH - 2004
Produced by: The British Committee for Standards in Haematology (BCSH) is a sub-committee of the British Society for Haematology (BSH).
Purpose: The purpose of this guideline is to provide a rational approach to the diagnosis and management of patients with chronic lymphocytic leukaemia.
Can be obtained from: British Journal of Haematology 2003; v120(1), p187-200 or British Society for Haematology, 100 White Lion Street, London N1 9PF. Tel: 020 8643 7305
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes - 2003
Produced by: British Society for Haematology (BSH).
Purpose: To provide haematologists with up to date advice on the diagnosis and treatment of haematological disease by the production of evidence based guidelines.
Can be obtained from: British Journal of Haematolgy 2003; v120(1), p187-200 or British Society for Haematology, 100 White Lion Street, London N1 9PF Tel: 020 8643 7305
Guidance on the use of imatinib for chronic myeloid leukaemia, 2003
Produced by: NICE, National Institute for Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA, October 2003, Technology Appraisal Guidance No.70.
This guidance replaces Technology Appraisal Guidance No. 50 issued in October 2002
Purpose: Clinical guidance on the use of imatinib in the treatment of chronic myeloid leukaemia.
Can be obtained from: Copies of this guidance can be ordered from the NHS Response Line by telephoning 0870 1555 455 and quoting ref N0340. A version for the public can be obtained by quoting ref N0337. A version in Welsh and English is also available, reference number N0338.
Guideline on the use of Colony Stimulating Factors in Haematological Malignancies - BCSH - 2003
Produced by: The British Committee for Standards in Haematology (BCSH) is a sub-committee of the British Society for Haematology (BSH).
Purpose: To provide haematologists with up to date advice on the diagnosis and treatment of haematological disease by the production of evidence based guidelines.
Can be obtained from: British Journal of Haematolgy 2003; v123(1), p22-33 or British Society for Haematology, 100 White Lion Street, London N1 9PF Tel: 020 8643 7305
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia, NICE - 2001
Produced by: National Institute for Clinical Excellence - NICE - September 2001 Technology Appraisal No.29
Purpose: To provide guidance to health professionals on the use of oral fludarabine. This is recommended as second line therapy for B-cell chronic lymphocytic leukaemia (CLL) for patients who have failed, or are intolerant of, first line chemotherapy, and who would otherwise have received combination chemotherapy.
Can be obtained from: NHS Response Line Tel: 0870 1555 455, quoting reference N0025
Guidelines on the diagnosis and therapy of Hairy cell Leukaemia - British Society for Haemotology - 2000
Produced by: British Committee for Standards in Haematology - The British Society for Haematology - 2000
Purpose: To provide guidelines on diagnosis and therapy
Can be obtained from: www.blackwell-science.com/uk/society/bsh/ or or British Society for Haematology, 100 White Lion Street, London N1 9PF Tel: 020 8643 7305
Alpha interferon in the treatment of chronic myeloid leukaemia - Wessex Institute - 1996
Produced by: The Wessex Institute for Health Research & Development - 1996 DEC Report No.52. This report has been prepared as part of the Development and Evaluation Service funded by the Research and Development Directorate, NHS Executive.
Purpose: To provide rapid, accurate and usable information on health technology effectiveness to purchasers, clinicians, managers and researchers.
Can be obtained from: R&D Directorate, NHS Executive South & West, Canynge Hall, Whiteladies Road, Bristol, BS8 2PR. Tel: 0117 9287224 Fax: 0117 9287204
Pentostatin and cladribine for hairy cell leukaemia - Wessex Institute - 1995
Produced by: The Wessex Institute for Health Research & Development - June 1996 DEC Report No.45. This report has been prepared as part of the Development and Evaluation Service funded by the Research and Development Directorate, NHS Executive.
Purpose: To provide rapid, accurate and usable information on health technology effectiveness to purchasers, clinicians, managers and researchers.
Can be obtained from: R&D Directorate, NHS Executive South & West, Canynge Hall, Whiteladies Road, Bristol, BS8 2PR. Tel: 0117 9287224 Fax: 0117 9287204
Guidelines on the provision of facilities for the care of adult patients with haematological malignancies. (including leukaemia, lymphoma and severe bone marrow failure.) – BCSH - 1995
Produced by: The British Committee for Standards in Haematology (BCSH) is a sub-committee of the British Society for Haematology (BSH).
Purpose: To provide haematologists with up to date advice on the diagnosis and treatment of haematological disease by the production of evidence based guidelines.
Can be obtained from: Clinical and Laboratory Haematology 1995; v17, p3-10 or The British Society for Haematology, 100 White Lion Street, London N1 9PF Tel: +44 (0) 20 8643 7305
Content last reviewed: 01 January 2002
Page last modified: 11 December 2006
Page last modified: 11 December 2006